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Abstract: Nano-pulse stimulation (NPS), previously called nsPEFs, induced a vaccine-like effect
after ablation of orthotopic N1-S1 hepatocellular carcinoma (HCC), protecting rats from subsequent
challenges with N1-S1 cells. To determine immunity, immune cell phenotypes were analyzed in naïve,
treated and protected rats. NPS provides a positive, post-ablation immuno-therapeutic outcome
by alleviating immunosuppressive T regulatory cells (Treg) in the tumor microenvironment (TME),
allowing dendritic cell influx and inducing dynamic changes in natural killer cells (NKs), NKT-cells
and T-lymphocytes in blood, spleen and liver. NPS induced specific increases in NKs and NKT-cells
expressing CD8 and activation receptors CD314-NKG2D and CD161 (NK1.1) in the TME after
treatment, as well as some variable changes in CD4+ and CD8+ effector (Tem) and central memory
(Tem) lymphocytes in blood and spleen. After orthotopic challenge, CD8+ T-cells were cytotoxic,
inducing apoptosis in N1-S1 cells; additionally, in contrast to post-treatment immune responses,
CD4+ and CD8+ memory precursor effector cells (MPECs) and short-lived effector cells (SLECs)
were present, while still including CD8+ CD161 NK cells, but not involving CD8+ CD314-NKG2D+
NKs. This immunity was N1-S1-specific and was sustained for at least 8 months. NPS vaccinates rats
in vivo against HCC by activating innate and adaptive immune memory mechanisms that prevent
HCC recurrence.
Keywords: effector memory T-cells; central memory T-cells; memory precursor effector T-cells;
short-lived effector T-cells; NK cell receptors; NKT cells; T-regulatory cells
1. Introduction
The liver is the largest internal organ in the body and serves a wide range of functions
related to digestion, nutrient storage, metabolism, detoxification and immunity among others.
The liver has a dual blood supply from the hepatic artery providing fresh oxygenated blood
and from the hepatic portal vein from the digestive tract delivering intestinal nutrients, bacterial
products, environmental toxins and drugs. The blood supply courses through a specialized
sinusoidal structural design that maximizes interactions between immune cells and pathogens.
Chronic hepatocyte injury and efferocytosis of dead and dying cells leads to production of
pro-inflammatory cytokines, linking hepatocyte apoptosis and liver fibrosis [1–4]. In contrast to
other homeostatic functions where programmed cell death is a silent, non-inflammatory process [5],
programmed cell death and inflammation, as part of liver homeostasis, is unique to hepatocytes.
Chronic liver inflammation promotes genetic instability that transforms cells, develops resistances
to apoptosis and immune surveillance, and facilitates hepatocellular carcinoma (HCC) resistances to
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chemotherapeutic agents [5,6]. Symptoms and diagnoses of HCC generally occur at advanced stages,
when prognoses are usually poor, so HCC incidence and mortality rates are nearly equal.
Liver cancer is the fifth-most common cancer, with over half a million cases every year [7],
and about 75% of these are HCC [8]. A recent report estimated that instances of liver cancer will
continue to increase through years 2020 and 2030 in the United States, becoming the number three
cause of cancer deaths by 2030, behind lung and pancreatic cancer [9]. HCC often begins with cirrhosis,
progressing to adenoma and dysplastic nodule formation [10]. Continual proliferation and tissue
regeneration leads to uncorrected mutations, giving rise to altered stem cells with greater chances for
further changes causing tumor progression [11].
Although not generally considered part of the immune system, like the spleen, lymph nodes and
thymus, the liver is in fact an immunological organ [12]. The liver’s innate lymphoid immune system
forms an immunological barricade to pathogen intrusion by distinct sets of antigen-presenting cells
(APC), including liver sinusoidal endothelial cells (LSEC), Kupffer cells, stellate cells and dendritic
cells (DCs). Also included in this defense system are enriched levels of natural killer (NK) cells
and NKT-cells, as well as T-lymphocytes with enhanced levels of CD8+ cells [13]. Given the liver’s
position in immune surveillance and innate immunity as first responders to pathogens and toxic
insults [12,14,15], tight regulation between tolerance and immunity must be maintained for differential
responses to non-pathogenic and pathogenic molecules [16,17].
For more than a decade, applications of nanosecond-pulsed electric fields (nsPEFs), now called
Nano-Pulse Stimulation (NPS), have shown ablation efficacy against a wide range of tumor types,
including HCC [18]. While not yet clinically available, NPS provides an additional HCC therapy to
other technologies using electric fields, which include electrochemotherapy (ECT) [19] and irreversible
electroporation [20], both of which have shown benefit for HCC in humans. Results presented here
indicate that NPS may provide additional significant advantages beyond ablation for HCC treatment.
NPS induced a post-HCC ablation, vaccine-like effect in rats [21] and triggered CD8+-dependent
inhibition of secondary HCC tumors in rats [22]. More recently, successful NPS treatment of mammary
cancer induced a vaccine-like effect that prevented breast cancer metastasis to spleen, lung and liver
and induced robust immune responses in orthotopic mammary cancer in mice [23]. NPS has also been
shown to induce release of immunogenic danger-associated molecular patterns (DAMPs) in several
tumor cell types [22–24]. The suspected immune response behind the vaccine-like effect protecting
rats from N1-S1 HCC challenge after ablation by NPS has not been investigated until now.
In this report, the hypothesis was tested that our previous finding of a protective, vaccine-like
effect after NPS ablation of rat HCC [21] was induced by immune responses observable in blood,
spleen and liver. We show that this post-ablation, vaccine-like effect is specific to N1-S1 HCC, not rat
H4IIE HCC, and is in fact mediated by robust innate and adaptive immune responses. Different
adaptive and innate immune responses are recalled in post-NPS ablation after orthotopic challenge of
N1-S1 cells. After NPS, rapid increases of specific NK and NKT-cell subsets appear in liver, as well
as by CD8+ and CD4+ effector memory and central memory T-cell responses in the HCC tumor
microenvironment (TME), spleen and blood. The immune responses to post-ablation challenge with
N1-S1 cells includes cytotoxic CD8+ T-cells and an immune response distinctly different from the
post-treatment response. These memory responses last at least 8 months, and an abscopal effect can
prevent secondary tumor growth when tumors are of limited size.
2. Results
2.1. NPS Induces an Adaptive Immune Response in Blood and Spleen after HCC Ablation
NPS Induces Changes in CD4+ and CD8+ Tem and Tcm Lymphocytes in Blood and Spleen
Central memory (Tcm) and effector memory (Tem) cells are distinguished from naïve T-cells by
the presence of CD44, which is involved in lymphocyte activation. Tcm and Tem cells are differentiated
by the presence and absence, respectively, of CD62L (L-selectin), which functions as a lymph node
Cancers 2018, 10, 69 3 of 19
adhesion/homing receptor. To determine if NPS induced an immune response after treatment of
rat orthotopic N1-S1 HCC tumors, CD4+ and CD8+ Tem cells (CD44+ CD62L−) and Tcm cells
(CD44+ CD62L+) were analyzed in blood (Figure 1) and spleen (Figure 2). In pre-treated tumor-bearing
rats, only CD4 Tem cells were elevated above naïve controls. During the 7-day post-treatment study,
only CD4+ Tcm were significantly elevated (5.2-fold, day 2), although CD8+ Tcm tended to be higher
(1.7–2.5-fold), but not with statistical significance. After NPS treatment, CD4+ and CD8+ Tem cells were
no different from pre-treated tumor-bearing rats. Over the 7-day study in spleen, CD4+ and CD8+ Tem
cells were significantly elevated (1.6-fold day 7; 1.4-fold, day 2, respectively), while CD8+ Tcm showed
a time-dependent increase to about 2-fold, but not with statistical significance. Generally, within the
first week after NPS treatment, blood and spleen levels of adaptive T-cells showed trends towards
increases, but variability among individual animals did not always allow statistical significance.
CD4+ and CD8+ memory precursor effector cells (MPECs: CD127+ KLRG1−) and short-lived
effector cells (SLECs: CD127− KLRG1+) were absent or present at very low unchanging levels in
response to NPS treatment during the study in spleen and blood.
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Figure 1. Circulating CD4+ and CD8+ Tem and Tcm increase in response to NPS. Blood was taken from
rats at various times post-Tx using Institutional Animal Care and Use Committee (IACUC) approved
methods. Lymphocytes were isolated using Ficoll, then stained with CD4, CD8, CD44 and CD62L;
analysis was done on CD4+ cells (A) and CD8+ cells (B). Error bars = standard error of the mean (SEM);
Naïve, 2 Days, 4 Days n = 4; Pre-Tx n = 2; 7 Days n = 5. CD44+/CD62L−, CD44+/CD62L+ 2 Days
Post-Tx: CD44+/CD62L+ 7 Days Post-Tx: p < 0.01.
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Figure 2. NPS induces increases in splenic CD4+ Tem and CD8+ Tem and Tcm after treatment.
Lymphocytes were isolated from spleen at various times post-treatment, then stained with CD4, CD8,
CD44 and CD62L; analysis was done on CD4+ cells (A) and CD8+ cells (B). Error bars = standard error
of the mean (SEM); Naïve, 2 Days, 4 Days n = 4; Pre-Tx n=2; 7 Days n = 5. A. CD44+/CD62L− 7 Days
Post-Tx: p = 0.02. B. CD44+/CD62L+ 2 Days Po t-Tx: p < 0.004; connecting lines p < 0.05.
2.2. NPS Induces Innate and Adaptive Immune Responses in Liver after HCC Ablation
2.2.1. Resolution of Treg Immunosuppression and DC Infiltration in the TME after NPS
In rat liver studies, analyses included the tumor-bearing middle liver lobe as the TME. In two
individual studies, all liver lobes expressed similar cell levels and phenotypes, indicating that the liver
functioned in unison with t presence of treated and untreated N1-S1 HCC tumors.
We analyzed hepatic immunosuppressive T-regulatory cells (Tregs) with CD4+ CD25+ FoxP3
phenotypes (Figure 3A) and dendritic cells (DCs) with CD11c phenotype (Figure 3B). Compared to
naïve rats, Tregs significantly increased over 13–15-fold, before regressing to naïve levels by day 7 post
treatment. By the 2nd day post treatment, DCs were significantly greater (7.0-fold), compared to
pre-treated rats before the Treg level had decreased. The alleviation of the immunosuppressive TME
and the entry of DCs show indications that immune responses can be initiated.
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Figure 3. Immunosuppressive Tregs dissipate while dendritic cells infiltrate the TME in response to
NPS. Lymphocytes were isolated from the liver of naïve rats and from rats at various times post-Tx and
stained with either (A) FOXP3/CD25/CD4 (naïve n = 4, others n = 2) or with (B) CD11c (Naïve n = 5,
Pre-Tx n = 4, 2 days n=4, all others n = 6); error bars = SEM. * p < 0.05.
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2.2.2. HCC and NPS Induce Multiple Phenotypic Changes in Liver Tumor-Infiltrating Lymphocytes (TILs)
Figure 4 shows CD4+ (A) and CD8+ (B) tumor-infiltrating lymphocytes (TILs) in the liver
TME. Generally, CD4+ and CD8+ TIL phenotypes were elevated above naïve levels in pre-treated
tumor-bearing rats, except that SLECs were essentially absent; CD4+ and CD8+ Tcm cells were
significantly increased. After NPS treatment, no TIL phenotype was elevated above the level for
pre-treated tumor-bearing rats; however, levels varied due to large variations among different animals.
While MPECs were absent in blood and spleen (text with Figures 1 and 2), they were present in the liver
TME, but with variable levels during the week following NPS treatment. Nevertheless, the presence
of CD127, the IL7Rα chain, indicates the presence of cells with proliferative and anti-apoptotic
potential for memory T-cells [25]. Given that these TILs are in the presence of Treg-dominated
immunosuppressive TME until day 4 (Figure 3), they are likely anergic or ineffective, as indicated
by the failure of tumor-bearing rats to survive without NPS treatment. It is likely that after NPS,
these cells and others like them are recruited to the treatment zone and become cytotoxic against tumor
cells and participate in immune responses.
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Figure 4. Tumor-infiltrating lymphocytes (TILs) change phenotypes in response to NPS in the liver.
Lymphocytes were isolated from rat livers (tumor bearing lobe) at various times post-Tx. Cells were
stained with CD4, CD8, CD44, CD62L, CD127 and KLRG1. Analyses were done on CD4+ cells (A) and
CD8+ cells (B). Error bars = standard error of the mean (SEM); Naïve n = 4, Pre-Tx n = 5; others n = 6;
* p < 0.05.
2.2.3. Dynamic Changes in Liver NK Cells, NKT-Cells and T-Lymphocytes in the TME after NPS
To analyze NK cells, NKT-cells and T-cells in liver, we used CD3 and CD56 phenotypes in
one approach and CD3 and CD161 phenotypes in another approach. This latter approach is more
commonly used in mice, but was used here for completeness, because these phenotypes have not been
investigated in rats. NK cells are CD3− and CD56+ or CD161+; NKT-cells are CD3+ CD56+ or CD161+
and T-cells are CD3+ CD56− or CD161−. Supplementary Figure S1 shows a typical flow cytometric
analyses of liver using the CD3 and CD56 phenotype approach. Natural killer (NK) cells defined
as CD56+ CD3− (upper left quadrant), NKT-cells defined as CD56+ CD3+ (upper right quadrant),
and T-cells defined as CD56− CD3+ (lower right quadrant) were analyzed in naïve pre-treated and rat
livers 2, 4, and 7 day a ter NPS treatment. These cells were also nalyzed using the CD3 and CD161
phenotype approach in the same way. Several of these experiments provided the bases for analyses
of NK, NKT- and T-cells using the CD3 CD56 approach, as shown in Figure 5A, and the CD3 CD161
approach, as shown in Figure 5B.
In Figure 5A, using the CD56 and CD3 approach, rat liver NK cell levels were relatively high
in naïve rat livers, while NK levels tended to be decreased in pre-treated rats and remain relatively
constant following NPS treatment, with no significant differences among them. NKT-cell levels were
significantly elevated 2.6-fold (day 4) above naïve levels, and remained elevated during the 7-day
study; however, treated levels were not elevated compared to pre-treated levels. Elevated levels of
T-cells were present in rat livers under all conditions.
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When these cells were analyzed using the CD161 and CD3 approach (Figure 5B), NK cell
levels tended to be higher than the CD56 CD3+ phenotype, but their levels did not change before
or after treatment. The CD161− CD3+ T-cell phenotype was also elevated before and after NPS
treatment. Pre-treated CD161+ CD3+ NKT-cells were elevated slightly, and then on day 4 were
elevated significantly above naïve levels, but were not elevated above pre-treated levels. CD161 is
known to be expressed predominantly on T-cells with memory phenotypes [26], so its presence is
likely important. Yet, a simple analysis of CD3, CD56 and/or CD161 phenotypes did not show changes
in the first week after NPS treatment. Nevertheless, a more in-depth phenotypic analysis did show
significant differences.
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. . . ti t i ti t - ll t i t
I ll r r ll r t er r s i li i t e liver. T f rt r
i ti te NK, NKT- and T-cells in liver, we focused on the CD3 CD56 phenotype approach
because it is more commo ly used in rat immune studies. Figure S2 shows an additional strategy
using CD3− CD56+ NK cells for expression of CD8, CD314-NKG2B and CD161 (NK1.1) in naïve
rats (left panels) livers and treated, tumor-regressing rat livers (right panel ). CD314-NKG2D is
well-chara terized activation receptor for detection and elimination of transformed cells [27],
a d CD161 is another known activati n marker rep rted to be present on memory T-cells [26]. Naïve rat
NK phenotyp s included expression of CD11b (bottom left panel) and relative low levels of CD8 and
CD161 (18.4%), as well as low levels of CD8 and CD314-NKG2D (17.9%). After NPS, th liver NK cell
population underwent several NPS-induced phenotypic changes, with decreased expression of CD11b
(bottom right panel) and increased CD8+ NK phenotypes with CD161 (57.5%) and CD314-NKG2D
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(57.3%) activation receptors. The same strategies were used to analyze CD3+ CD56+ NKT-cells and
CD3+ CD56− T-cells (not shown). Figure 6A,B shows these studies for NK and NKT-cells, respectively.
Consistent with the results shown in Figure 4, the changes in T-cell CD3+ CD56- phenotype were less
remarkable and are shown in Figure S3.
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Figure 6. NPS induces an increase in various phenotypic subsets of NK and KT-cells. Liver lymphocytes
were analyzed with CD8a, CD314 (NKG2D) and CD161 on (A) NK cells (CD56+/CD3−) and (B) NKT-Cells
(CD56+/CD3+). Naïve n = 4, Pre-Tx n = 5; others n = 6; error bars = SEM. * p < 0.05.
Figure 6A shows that NPS treatment induced a time-dependent increase in NK cells after
treatment, with significant increas in CD8 and CD314-NKG2D (1.9-fold, day 4), as well as NKs
that expressed CD8 CD161 (1.4-fold, day 4). NK cells with CD314-NKG2D and CD161 were also
significantly increased by day 4 post NPS treatment. Figure 6B shows that NKT-cells also showed
NPS-induced increases in CD8+ CD314-NKG2D+ phenotype (2-fold, day 4), albeit not significantly,
and significant increases in CD8+ CD161+ phenotype (1.4-fold, day 4). In general, expression of these
markers was higher in NKs than in NKT-cells. Unlike NK cells, NKT-cells also showed a trend toward
increased levels of subsets without CD8, with or without CD314-NKG2D and CD161. Thus, in order
to see dynamic changes of NPS-induced effects on NK and NKT-cells, analyses of subsets with CD8,
CD314-NKG2D and CD161 phenotypes were needed.
Our analysis of Tem and Tcm T-cells in Figure 5 did not include an analysis of CD3+ CD56−
T-cell phenotypes considering CD314 or CD161 expression. Figure S3 shows that most T-cells defined
as CD3+ CD56− were more CD8a+. Those 8a T-cell subsets tended to decrease with time after
treatment, regardless of their expression of CD314-NKG2D or CD161. One T-cell subset that was
CD8a− CD161+ increased 2 days (2.0-fold) and 4 days (2.7-fold) after NPS, suggesting an activated
phenotype. These results suggest that liver CD8+ T-cells that express CD314-NKG2D or CD161 are
relatively rare and are likely less important for NPS-induced tumor elimination.
2.3. Immune Responses Mediating the Protective, Vaccine Effect after Challenge Injections
2.3.1. CD4+ and CD8+ Immune Response in Blood in the Post-Challenge, Vaccine Effect
To analyze the immune response during vaccine-like effect, blood was analyzed for various
lymphocyte phenotypes at various times before and after challenge (Figure 7). None of these rats had
developed tumors at nine weeks after the challenge injections. In general, changes in CD4+ phenotypes
were more dynamic than in CD8+ phenotypes. Compared to pre-challenged rats, there was an increase
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in CD4+ Tem on day 6 (1.6-fold), followed by a time-dependent decrease to pre-challenge levels
4–5 weeks after challenge. CD8+ Tem cell levels increased in pre-challenged rats 4.1-fold above naïve
levels (25.5%, Figure 7B vs. 6.3% in naïve rats, see Figure 1B) and remained elevated, but did not
change for 5 weeks in the post-challenge study. CD4+ and CD8+ Tcm cells were also elevated above
naïve levels (see Figure 1A,B, respectively), but did not show significant changes after challenge.
Thus, after NPS-induced tumor clearance, protected rats expressed elevated levels of CD4 and CD8
Tem and Tcm lymphocytes. Except for CD4+ Tem cells, these did not increase after challenge injections.
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Figure . Circulating T-Cells post-challenge show dynamic changes i CD4+ cells. Blood was harvested
at arious times po t-challenge. Lymphocytes were isolated using Ficoll a d then stained with CD4,
CD8, CD44, CD62L, CD127 and KLRG1. Analyses were done on CD4+ cells (A) and CD8+ cells (B).
n = 9, error bars = SEM. * p < 0.05.
The subset of MPECs that up-regulate and retain the IL-7Rα, CD127 form functional memory cell
pools, while SLECs that express KLRG1 are effector cells, but are terminally differentiated. After NPS
treatment, CD4+ and CD8+ MPEC (CD127+ KLRG1−) and SLEC (CD127- KLRG1+) cells were present
at v ry low levels (data not shown f om Figures 1 and 2), suggesting that they do not play a role
in the post-treatm t immune response. In contrast, after challenge, there was a time-dependent
6.6-fold increase above pre-chall nge levels in CD4+ MPECs, with significant increase in weeks
3–5 (Figure 7A). However, no CD8+ MPECs were observed post-challe ge (Figure 7B). CD4+ SLECs,
which are absent after NPS, increased 2.1-fold above pre-challenge levels at 6 days post-challenge,
and exhibited significant increases in 4 weeks post-challenge (Figure 7A). Levels of SLECs were
consistently low at 3 weeks post-challenge, suggesting that terminally differentiated SLECs fluctuate
during response to challenge. Interestingly, CD8+ SLECs were present in elevated levels before and
after challenge injections (Figure 7B). It appears that MPEC and SLEC lymphocytes play a greater role
in the vaccine-like, recall response to challenge than they do in response to initial tumor initiation.
2.3.2. CD4+ and CD8+ Immune Responses in Spleen and Liver during the Post-Challenge Vaccine-Like Effect
Figure 8 shows changes in CD4+ lymphocyte phenotypes in spleen (8A) and liver (8B) in
the first 3 weeks after protected rats were orthotopically challenged with N1-S1 cells. In general,
CD4+ phenotypes in spleen and liver did not show significant differences from naïve rats after
challenge, except in spleen for Tem cells in weeks 1 and 3, and Tcm in week 1, and in liver for
Tcm 3 weeks after treatment. Unlike in blood after challenge, CD8+ MPECs are present in the
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spleen and liver of pre-challenge rats at relatively high levels that remain three weeks after challenge.
Additionally, in contrast to blood, SLE cells were essentially absent or at relatively low, variable levels
in the spleen and liver after challenge.
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Figure 9 shows ch ges in lympho yt phenotypes in sple n (9A) and liver (9B) in the first
3 weeks after challenge. Significant increases were seen in spleen CD8 Tem and Tcm cells 3 weeks
after challenge and in liver CD8+ Tem and Tcm cells 1 week and 3 weeks, respectively, after challenge.
MPECs were relatively elevated in the spleen and low in the liver before and after treatment. SLECs
were very low in the spleen and variable in the liver before and after treatment.
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2.3.3. Splenic CD8+ Lymphocytes Are Cytotoxic after NPS-Induced Protection
To determine possible T-lymphocyte cytotoxicity after challenge, we isolated CD4+ lymphocytes
(92% pure) and CD8+ lymphocytes (96% pure) from spleens of naïve rats and rats two weeks after
treatment with only 2.2 and 1.4% cross contamination, respectively (Figure S4). Isolated lymphocytes
were incubated with Cell Tracker Violet-labeled N1-S1 cells, which were analyzed for active caspases
and Annexin-V binding as apoptosis markers 24 h later (Figure 10). N1-S1 cell percentage for
active caspases (red bars) and caspases plus Annexin-V (blue bars) are indicated on the Y-axis when
lymphocytes to N1-S1 ratios were 5:1, 10:1 and 30:1, as shown on the X-axis. CD4+ lymphocytes
showed no increases in cytotoxicity; there were no increases in either indicators of NPS N1-S1
cells (NPS) compared to non-NPS N1-S1 cells (N). In contrast, compared to non-treated N1-S1 cells,
CD8+ lymphocytes from NPS treated rats exhibited 1.5-, 2.2- and 1.7-fold more active caspase positive
N1-S1 cells, respectively, and 7.3-, 6.3- and 1.5-fold more caspase/Annexin-V double positive N1-S1
cells, respectively. However, statistically significant cytotoxicity was only observed in CD8+ T-cells
for increases in caspase activity when the ratios between lymphocytes and N1-S1 cells were 10:1 and
30:1. These results indicate that CD8+, but not CD4+, lymphocytes from spleens of protected rats after
challenge are cytotoxic towards N1-S1 cells treated with NPS compared to cells not stimulated by NPS.
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Figure 10. Splenic CD8+ T-cells are more cytoto i t splenic CD4+ T-cells. T-cells isolated from
spleens of rats 2 weeks post-NPS. N1-S1 cells were incubated ith separated CD4+/CD8+ T-cells for
16 h and prepared for flow cytometry. All analysis was done on the CellTrace+ N1-S1 cells. n = 3 and
error bars = SEM. Connecting lines p < 0.05.
2.3.4. Distinct Subsets of NK Cells in Liver and Spleen in NPS-Induced Post-Challenge Vaccine-Like Effect
Figure 11 shows CD3− CD56+ NK su t i the liver ( 1A) and spleen (11B) in the first and the
second week after protected rats were challeng d. The immune profile in the post-challenge liver looks
very different from the NK profile after initial NPS treatments (Figure 6). Unlike post-treatment levels,
NPS-induced NK cells that expressed increased CD8+ CD314-NKG2D+ were absent after challenge.
The post-challenge liver was now occupied primarily by CD8+ CD161+ NK subsets. These phenotypic
characteristics were also present in spleen, except at lower levels. The spleen had CD8+ CD161−
and CD8− CD161+ subsets, which were not elevated in the liver. The CD314+ NK subsets that were
present after initial treatment were absent after challenge.
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2.4. Analyses of NPS-Induced Response in Whole Animals
2.4.1. NPS Induces a N1-S pecifi Long-Lasting Post-HCC Ablation Vaccine-Like Effect in Rats
To determine if the NPS post-ablation vaccine-like ffect was specific to N1-S1 HCC, 7 weeks after
NPS reatment, tumor-free rats were o thotopically challenged with N1-S1 cells or with rat H4IIE HCC
cells. Three weeks later, N1-S1 tumor cells had not formed tumors. In contrast, H4IIE cells induced
tumor cell growth not as a defined tumor mass like that bserved for N1-S1 tumors, but as tumor cells
infiltra ing into, but distinctly d fferent from, normal liver parenchyma. This demonstrated that the
protective, vaccine-like effect after N1-S1 ablat on is specific to N1-S1 HCC.
To determine the longevity of the NPS post-abl tion vaccine-like effect in rats with ortho opic
N1-S HCC [21], a study with 6 rats was carried out over 11 (4 rats) o 15 (2 rats) months from tumor
initiation to study end (see materials nd methods). Four rats were challenged at 8 weeks and two
others at 14 and 19 weeks after reatment. None of these rats had developed tumors. These rats were
then boosted twice two months later, and then ortho opically challenged 6–7 months after booster
injection. None of these rats established tumors. The vaccine-l k effect and granzyme B expression in
the NPS treated TME [21] sugge ted an immune response, as d monstrated in his study.
2.4.2. NPS Induces a Limited Abscopal Effect
Two different abscopal models were analyzed in the rat N1-S1 model. When one-week-old
orthotopic tumors in the medial lobe (148.8 ± 69.3 mm3, n = 6) were treated and a second orthotopic
tumor cell bolus in the left lobe was initiated at the same time (same cell number as primary tumor),
three weeks later the treated tumors had regressed (28.4 ± 16.1 mm3) and the second tumor was not
established (0 mm3). This indicates that when a second tumor has escaped the primary site and is
seeded as in a micrometastasis at a distant site, NPS treatment of the primary tumor can prevent
growth of the distant second tumor.
When a primary tumor in the medial lobe (163.6 ± 23.9 mm3) and a secondary tumor in the left
lobe (59.6 ± 21.9 mm3) were established at the same time (n = 6), and the primary tumor was treated
one week later, two weeks after treatment, the primary tumor had regressed (107.4 ± 30.5 mm3),
but the secondary tumor had progressed (3182.5 ± 512.4 mm3).
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Thus, NPS initiates an immune response from a primary tumor treatment that is sufficient to
prevent the growth of a distant tumor while it is initiating, but not once the tumor is established.
NPS treatment of primary tumors ablates those tumors, resolves the immunosuppressive TME and
initiates an immune response; however, that immune response cannot resolve a tumor that has already
established an immunosuppressive TME.
3. Discussion
The studies presented here provide a general overview of how the innate and adaptive immune
system in rats with orthotopic N1-S1 HCC tumors respond before and after NPS treatment, and how
NPS induces a vaccine-like effect that prevents recurrence when orthotopically re-challenged with
N1-S1 HCC cells. Immune responses are of interest because NPS treatment itself essentially vaccinates
animals in vivo. The success rates of re-challenge are essentially 100%. In a previous study, 21 of
21 rats were protected [21], and scores of rats were protected during this study; protection lasted for as
long as 8 months. The NPS-induced vaccine-like effect is not unique to HCC or to rats. It was also
observed after NPS ablation of 4T1-Luc mammary cancer tumors in mice [23]. Vaccinations in these rats
were specific to N1-S1 HCC tumors; challenge with rat H4IIE HCC induced liver tumors in all 4 rats
tested. These studies demonstrate that the protective, vaccine-like effect following NPS ablation [21] is
mediated by multiple immune mechanisms appearing after NPS treatment involving elimination of
the immunosuppressive TME combined with both adaptive and innate immune mechanisms with
influxes of adaptive memory T-cells and specific subsets of NK and NKT-cells expressing activation
phenotypes. Although the NPS-induced immune-mediated vaccine-like effect does not specifically
constitute typical immunotherapy, NPS does achieve a major immunotherapy goal in exploiting
adaptive and importantly innate immune cells in order to destroy tumors [28].
The inept immune response from immune cells with activation markers in the untreated HCC TME
was due in part to significantly elevated Tregs (Figure 3A). Although not determined here, Tregs are
known to secrete immuno-inhibitory cytokines, such as IL-10, IL-35 and TGFβ, and interact with DCs
in the TME that inhibit T-cell effector functions, induce T-cell anergy, prevent T- and B-cell proliferation,
and inhibit NK, DC and macrophage anti-tumor functions [29]. The TME plays multiple roles in
tumor progression, epithelial-mesenchymal transition and drug resistance, as well as angiogenesis
and metastasis [30]. Without NPS treatment, the immunosuppressive TME prevents effective innate
and adaptive immune responses, requiring humane euthanasia 2–3 weeks after tumor initiation due to
tumor burden [21].
NPS treatment changes the immunosuppressive sequela in the TME and effectively eliminates
HCC in these rats by several mechanisms. NPS induces regulated cell death (RCD) in the
TME [21], which is known to induce immunogenic cell death (ICD) [31–34]. To eliminate tumors
and induce an immune response, it is surprising that such intense conditions (50 kV/cm, ~10 MW),
require 1000 pulses in rat HCC [21, this study] and mouse mammary cancer tumors [23].
However, this includes only 0.1 msec of NPS exposure time. Yet afterwards, Tregs regress and
DCs increase (Figure 3) for antigen recognition. In the metastatic 4T1 mammary cancer model,
NPS treatment significantly decreases Tregs and myeloid-derived suppressor cells (MDSCs) in the
TME and blood [23]. NPS does not selectively eliminate tumor cells in the TME. Tumor cell death is also
promoted by death of tumor stroma tissues such as host somatic cells and macrophages, which promote
tumor growth, stimulate immune suppression, and interact with cancer stem cells, contributing to
tumorigenesis, drug resistance and metastasis [35]. Since NPS eliminates significant cell numbers in
the TME, immune cells present after the first few days most likely represent some surviving cells and,
more importantly, the influx of cells from the surrounding liver tissue. These are first represented by
NK and NKT-cells that expressed CD314-NKG2D and CD161 activation receptors, presumably with
cytotoxic activities as shown by expression of granzyme B after treatment [21].
For analyses of NK and NKT-cell phenotypes with CD3 and CD56 or CD161, only CD3+ CD161+
NKT-cells showed NPS-induced elevation (Figure 5). However, a closer phenotypic investigation
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indicated that NPS specifically induced NK and NKT-cell subsets with CD8+ and CD314-NKG2D
and/or CD161 (Figure 6). These cell subsets likely played an important role in HCC tumor elimination
after NPS, as well as bridged the gap between innate and adaptive immunity. Given that CD8+
CD314-NKG2D NK and NKT-cells (Figure 6) were only present after treatment, but not after tumor-free
rats were challenged (Figure 11), and that NKG2D is the most important NK activation receptor
expressed in NK cells regarding virus-infected cells and tumor-cell recognition based on expression of
stress ligands on target cells [27], it is likely that NPS induced NK-recognized “stress” ligands during
tumor cell death. Some NK cell ligands have been identified in humans and mice [27], but none in
rats. Known CD314-NKG2D ligands are all homologous to MHC I class molecules and are either
transmembrane proteins or are linked to glycosylphosphatidylinositol [27]. When stress is defined as
tumorigenesis, infection or injury, there are several common factors that can activate NKG2D receptors,
including DNA damage responses, programmed cell death, upregulation of heat shock pathways,
unfolding protein response, oxidative stress, and inflammation. After NPS, tumor cells are severely
distressed, but do not die immediately. DNA damage and active caspases can be seen hours after
treatment [21,24]. These stress responses also cause the release of ICD molecules [23,24] and molecules
with DAMPs that activate pattern recognition receptors (PRRs), such as Toll-, NOD- and RIG-like
receptors (TLR, NLR, RLRs). Recognition of hepatitis C virus by TLRs [36] and dsRNA after viral
infection by RLRs [37] induces expression of various N KG2D ligands, raising the possibility that
signaling through PRRs can induce expression of NKG2D ligands.
NK cells do not express T-cell or B-cell antigen receptors. Instead, NKs integrate fixed numbers
of inhibitory and activating receptors that determine NK cytotoxicity and cytokine release [38].
NK cells can be activated by at least two different mechanisms. To be functional, NKs must
first be “licensed” by binding self MHC class 1 molecules with inhibitory receptors. When MHC
class I molecules are down-regulated on tumor cells to avoid T-cell recognition, this “missing self”
receptor disengages inhibition signaling, slanting the balance toward activating signals [39,40].
Simultaneously, NK receptors identify “stress ligands” or “altered self” molecules that are not present in
normal cells, but are upregulated in transformed cells. These are readily recognized and activated in NK
cells expressing CD314-NKG2D stimulatory receptors [27]. Engagement of the CD314-NKG2D receptor
is known to overrule inhibitory receptors and activate NK cells [27]. In this study, inhibitory receptors
were not characterized, primarily because antibodies are not available for these receptors in rats.
Since the liver is an innate immune organ [14], analysis of immune response to HCC in the liver
was of specific interest, especially for first-responding NK cells. Rat NK cells are not well-characterized,
but mice NKs are in Group 1 of three innate lymphoid cell groups (ILCs) based on cytokine production
and transcription factors (TFs) regulating development and functions [41]. The TFs Eomes and
T-bet are regulated differently in bone marrow and liver, giving rise to two distinct ILC group
1 NK sub-groups [42]. Fully functional NKs develop in fetal mouse liver and remain in adults,
suggesting distinct liver NK precursor cells [43]. Rat NKs have been characterized primarily by
morphology. There are “liver-specific” large granular lymphocytes (LGL) called pit cells, which are
equivalent to mouse liver NKs [44]. These cells were further characterized as low-density (LD)
and high-density (HD) pit cell/NK cells in liver. The LD NKs are akin to activated NKs as early
defense against infections and cancer [45–47], and are likely related to NPS-activated NKs expressing
CD314-NKG2D and CD161 (NK1.1) receptors. Human and rat hepatic NK cells lyse tumor cells that
are resistant to splenic or blood NK cells [48], indicating that liver NKs are different from circulating or
splenic NKs, but are likely recruited from blood and “educated” in liver to provide distinct functions.
While our study did not compare liver to blood or spleen NKs, we did show that tumor-bearing
NKs are phenotypically different from naïve NKs (Figure S2), and NPS liver NKs are different from
tumor-bearing NKs before NPS treatment (Figure 6). It is likely that transient presence of liver NKs
expressing CD8 with CD314-NKG2D and/or CD161 activation receptors are recruited to, “educated” in
and activated by NPS in the liver.
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The immune response in vaccinated rats to orthotopic challenge injections presented a somewhat
different immune landscape than that seen after NPS treatment. While there were variable increases
in CD4+ and CD8+ Tem and Tcm cells in blood, spleen and liver (Figures 7–9) after treatment,
there were significant increases in CD4+ MPECs and CD4+ and CD8+ SLECs in blood (Figure 7)
that were not present after treatment. These MPEC were also elevated in the liver and spleen. This
response is similar to the resolution of an acute infection when T-cells differentiate into MPECs
expressing CD127 and elevated levels of BCL2 that are destined to provide long-term memory and
SLECs expressing KLRG1 that have been repeatedly stimulated by antigens and undergo terminal
differentiation and cellular senescence [49,50]. However, the responses here were more apparent in
the CD4+ population, while CD8+ MPECs were essentially absent. Nevertheless, after challenge
injections, CD8+ lymphocytes were cytotoxic against N1-S1 cells when they were treated with NPS
(Figure 10). Also of interest was the absence of NK and NKT-cells expressing CD8 and CD314-NKG2D
phenotype in liver after challenge, which was specifically elevated after NPS treatment. In contrast,
NK and NKT-cells expressing CD8 and CD161 were specifically elevated after treatment and present
after challenge. The CD161 receptor on T-cells can act as a co-receptor defining a specific T-cell
subset [51] that secrete IL-17, which among other functions, recruits and activates granulocytes to
promote inflammation [52]. The CD161 is also present on memory T-cells, suggesting that CD161+ NK
and NKT-cells could uniquely carry memory immune mechanisms [26]. NK cells [53,54] and other
innate immune cells [55,56] have recently been shown to be capable of immunological memory.
Other methods using electric fields, including electrochemotherapy (ECT) with bleomycin
and irreversible electroporation with calcium recently induced similar vaccine-like effects in
murine CT26 colon carcinoma cells [57], but the immune mechanisms remain to be investigated.
Furthermore, ECT with bleomycin induced a systemic immune response in a melanoma patient [58].
Here, we characterize the NPS-induced adaptive immune responses in blood, spleen and liver,
which lasts for months in rats treated for HCC. Robust innate immune response is induced specifically
by NPS in liver NK and NKT-cells expressing dominant activation receptors CD8+ CD314-NKG2D
and/or CD161. The immune response after orthotopic challenge is distinct compared to after treatment
with enhanced involvement of MPECs and SLECs and CD8+ NK and NKT-cells with an absence of
CD314-NKG2D but a presence of CD161. An abscopal response is present in less well-established
tumors, indicating that in established tumors, an immunosuppressive TME can become dominant
in spite of the presence of NK, NKT and T-lymphocytes. However, NPS treatment can reserve this
suppression and establish innate and adaptive immune response as tumors are regressing to establish
the NPS-induced protective vaccine-like effect characterized here in rat HCC and in mouse metastatic
breast cancer [23].
4. Materials and Methods
4.1. Animals and Cell Culture
Male Sprague Dawley rats (6–8 weeks, Envigo, Huntingdon, UK) were cared for and housed
in an Association for Assessment and Accreditation of Laboratory Animal Care International
(AAALAC, Frederick, MD, USA)-approved facility, and all procedures were carried out with the
approval of the Old Dominion University Institutional Animal Care and Use Committee (IACUC).
Rat N1-S1 HCC cells (American Type Culture Collection, ATCC, Rockville, MD, USA) were
cultured as previously described [21].
4.2. The HCC Model and Nano-Pulse Stimulation Treatment
For tumor initiation in the orthotopic model, the median liver lobe was exposed through an
incision in the abdomen, and 1 × 106 N1-S1 HCC cells in 50 µL saline were injected under the
liver capsule. Seven days later, the tumor-bearing lobe was exposed again, and tumors were either
sham-treated (electrodes inserted, not pulsed) or treated with NPS delivering 1000 pulses (1–3 pulses/s)
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with 100 ns durations and electric field strengths of 48–52 kV/cm. Challenge studies were initiated
6–7 weeks after NPS treatment. Animals were euthanized at various times post-treatment and
challenged as indicated in the text and Figures.
A long-term challenge study with 6 rats began by tumor initiation (1 × 106 cells) and treatment
1 week later. Rats were then orthotopically challenged (1 × 106) 8 (n = 4), 14 and 19 weeks later.
All of these tumor-free rats were then challenged by subcutaneous booster injections of N1-S1 cells
at 6 weeks, and again at 8 weeks later (1 × 106) (i.e., booster injections separated by 2 weeks).
Subcutaneous injected cells did not form tumors in naïve or NPS-treated rats. Then, 6 months (n = 2)
and 7 months (n = 4) after the last boost injection, rats were orthotopically challenged (1× 106) a second
time. Three weeks after this second challenge injection, rats were humanely euthanized. No tumor
growths were found on any livers.
4.3. Splenocyte Preparation
Whole spleens were harvested, minced with scissors in RPMI 1640 supplemented with
L-glutamine, 25 mM HEPES and 10% FBS and forced through a 40 µm cell strainer
(Fisherbrand, Waltham, MA, USA). Cells were spun (350× g, 5 min, 4 ◦C), pellets resuspended,
and washed with 1× PBS. Cells were finally suspended in 10 mL of ACK Red Blood Cell (RBC)
Lysis Buffer (KD Medical, Columbia, MD, USA), incubated (dark, room temperature) for 7 min and
then diluted with 40 mL of 1× PBS. The cells were spun again, and the pellets were suspended
(1 × 106/mL) in flow cytometry FACS buffer (5% fetal calf serum in 1× PBS). Cells were then stained
for flow cytometry.
4.4. Blood Preparation
Blood was collected in 5 mM EDTA tubes from anesthetized rats via jugular veins (~500 µL) or
end-of-life cardiac puncture (~1 mL). Blood was diluted 1:1 in PBS and layered on 3mL of Ficoll-Paque™
PLUS (GE Healthcare, Little Chalfont, UK) and spun (400× g, 30 min, 4 ◦C). The interphase containing
the lymphocytes was collected and washed with FACS buffer. The cells were washed, and pellets were
resuspended in FACS buffer (1 × 106/mL). Cells were then stained for flow cytometry.
4.5. Liver Preparation
After euthanasia, liver lobes or tumors were harvested and placed in 15 mL complete RPMI
1640. Livers/tumors were minced using scissors and a razor blade (without enzymes) until only small
chunks remained. The suspensions were filtered through 200 µm filters (PluriSelect, Leipzig, Germany)
and then 40 µm cell strainers. Cells were suspended in 50 mL PBS, spun at (350× g, 5 min, 4 ◦C).
The pellet was layered on top of 5 mL of Ficoll-Paque™ PLUS, spun (400× g, 30 min, 4 ◦C), and the
lymphocyte layer was collected. Cells were washed and resuspended in FACS buffer (1 × 106/mL).
Cells were then stained for flow cytometry.
4.6. Flow Cytometry and Antibodies
All flow cytometry and analysis was done on an Aria FACS Diva flow cytometer equipped with
3 lasers, and all analysis was done with the FACS Diva software. The following antibodies were used in
specific phenotypic panels: T-Cell Panel: CD4-APC-Cy7 (Biolegend, San Diego, CA, USA), CD8a-V450
(BD Horizon San Jose, CA, USA), CD44-FITC (ThermoFisher Scientific, Waltham, MA, USA),
CD62L-eFluor660 (eBiosciences, San Diego, CA, USA), KLRG1-Biotin (BD Pharmingen, San Jose,
CA, USA) with Streptavadin-Alexa Fluor 430 (ThermoFisher Scientific) as the secondary, and CD127-PE
(R&D Systems, Minneapolis, MN, USA). NK Cell Panel: CD56-Alexa Fluor 700 (Novus Biologicals,
Littleton, CO, USA), CD314-PE (ThermoFisher Scientific), CD3-FITC, CD161-APC, CD8a-PerCP
all from Biolegend. DC Panel: CD11c-FITC (Bio-Rad, Hercules, CA, USA), CD86-PE (Biolegend),
and MHC Class II-APC (Miltenyi Biotec, Teterow GER). Treg Panel: FoxP3-PE, CD4-APC and
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CD25-FITC all from Biolegend. All antibodies were used at the company’s suggested concentration or
titrated for optimal use.
4.7. Cytotoxicity Assay
Spleens were isolated from Sprague Dawley rats at various times post-treatment and post-challenge.
Splenocytes were isolated as described above. CD4 and CD8 T-cells were separated with negative
selection using CD4 and CD8 T-Cell Isolation kits (StemCell Technologies, Vancouver, BC, Canada).
The cross-contamination purity of a typical preparations of CD4+ and CD8+ lymphocytes is
shown in Figure S4. N1-S1 cells were labelled with CellTrace Violet (ThermoFisher Scientific,
Waltham, MA, USA) according to manufacturer’s instructions. Various ratios of T-cells to labelled
N1-S1 cells (5:1, 10:1 and 30:1) were incubated together at 37 ◦C, 5% CO2 for 24 h. The cells were
harvested and stained with Annexin-V (APC) (ThermoFisher Scientific, Waltham, MA, USA) in annexin
binding buffer (1× PBS, 10 mM Hepes, 150 mM NaCl, 2.5 mM CaCl2) and CaspACE FITC-VAD-FMK
(Promega, Madison, WI, USA) at room temperature for 20 min. The cells were washed and propidium
iodide was added before running on flow cytometry. Cytotoxicity was indicated.
4.8. Statistics
Statistical analysis was done by performing a comparison of means by T-test. Significance was
determined by using a p-value ≤ 0.05. The use of out-bred Sprague Dawley rats and variabilities
among them, determination of cell phenotypes over long periods of time and, in some instances,
the inclusion of small number of animals, presented conditions that sometimes did not allow values to
reach statistical significance. Nevertheless, there were obvious trends that demonstrated changes that
were considered meaningful.
5. Conclusions
The studies presented here and the studies by Guo and colleagues [23] are the first reports to
demonstrate directly that NPS induces immune memory responses in rats and mice, respectively.
Furthermore, these immune responses are multifaceted. In addition to showing that Tem and Tcm cells
are present in blood and spleens in both studies, the study here further shows that there is a robust
innate immune response in the liver and spleens of rats treated with NPS for HCC. NPS up-regulates
subsets of NK and NKT-cells that express CD8+ and CD314-NKG2D that are specific to NPS treatment.
In contrast, NK and NKT-cells that express CD8 and CD161 are specifically induced after treatment and
present after challenge, suggesting they may represent memory cells. MPECs are also prominent after
challenge. NPS also resolves the immunosuppressive TME by decreasing Tregs, as well as MDSC in
the study by Guo et al., in TME and blood [23]. Thus, NPS induces both innate and adaptive immune
responses in rats that eliminate the primary disease and prevent recurrence.
Supplementary Materials: The following are available online at www.mdpi.com/2072-6694/10/3/69/s1. Figure
S1: Flow cytometry NK cell analysis using CD56 and CD3 as the defining markers, Figure S2: Flow cytometry
shows NPS activates CD8+ NKs to initiate immune responses in rat HCC, Figure S3: T-Cell analysis post-NPS
show differences of various surface markers in response to NPS, Figure S4: Flow cytometry confirms separation
purity of CD4+ and CD8+ T-cells.
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